Hiroki Inada

8PUBLICATIONS

24CO-AUTHORS

Disease surveillancePredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsTissue engineering

Get your video featured.

Publish with JoVE

Get your video featured.

Publish with JoVE

Publications (8)

Sort by Publication Date:

|May 06, 2026

Rifaximin Improves Cognitive Performance and Reduces Cirrhosis-Related Adverse Events in Covert Hepatic Encephalopathy: A Randomized Controlled Trial.

|Mar 18, 2026

Impact of Etiological Shifts and the Rising Burden of Non-B Non-C Hepatocellular Carcinoma on Surveillance and Prognosis: Insights From a 20-Year Retrospective Observational Study.

Yoko Yoshimaru, Katsuya Nagaoka, Hiroko Setoyama

|May 03, 2025

Serum alpha-fetoprotein/hepatocyte growth factor ratio as a novel biomarker predicting the prognosis of acute alcoholic hepatitis.

Hiroki Inada, Katsuya Nagaoka, Kenyu Hashimoto

|May 03, 2025

Neutrophil-to-lymphocyte ratio at the start of the second course of durvalumab plus tremelimumab therapy predicts therapeutic efficacy in patients with advanced hepatocellular carcinoma: A multicenter analysis.

Takanori Suzuki, Kentaro Matsuura, Satoshi Sobue

|Nov 29, 2023

Randomized phase I/II study of vascular endothelial growth factor receptor peptide vaccines for patients with hepatocellular carcinoma.

Yoko Yoshimaru, Katsuya Nagaoka, Kentaro Tanaka

|Mar 11, 2023

Therapeutic Modifications without Discontinuation of Atezolizumab Plus Bevacizumab Therapy Are Associated with Favorable Overall Survival and Time to Progression in Patients with Unresectable Hepatocellular Carcinoma.

Takayuki Tokunaga, Masakuni Tateyama, Yasuteru Kondo

Pageof 2

Frequent Collaborators

Yasuhito Tanaka

Takayuki Tokunaga

Katsuya Nagaoka

Satoshi Narahara

Hiroko Setoyama

Takehisa Watanabe

Yasuyuki Ohkawa

Masao Nagasaki

Yoshihiro Ogawa

Atsushi Suzuki

Frequent Collaborators

Yasuhito Tanaka

Takayuki Tokunaga

Katsuya Nagaoka

Satoshi Narahara